Ranbaxy recalls drug in US

India’s leading drug maker has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

This is the second instance in four months when has initiated a recall. In July, the company had pulled out a lot of Sotret from the US market after it was found to be degraded. Confirming the development, a company spokesperson said the recall was carried out voluntarily and was limited to a single lot of Sotret 40 mg tablets.

According to the (USFDA), the recall comes under the Class III category, which implies that the use of or exposure to the product that is being recalled is unlikely to have any adverse health impact.

image
Business Standard
177 22
Business Standard

Ranbaxy recalls drug in US

BS Reporter  |  New Delhi 

India’s leading drug maker has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

This is the second instance in four months when has initiated a recall. In July, the company had pulled out a lot of Sotret from the US market after it was found to be degraded. Confirming the development, a company spokesperson said the recall was carried out voluntarily and was limited to a single lot of Sotret 40 mg tablets.

According to the (USFDA), the recall comes under the Class III category, which implies that the use of or exposure to the product that is being recalled is unlikely to have any adverse health impact.

RECOMMENDED FOR YOU

Ranbaxy recalls drug in US

India’s leading drug maker Ranbaxy has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

India’s leading drug maker has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

This is the second instance in four months when has initiated a recall. In July, the company had pulled out a lot of Sotret from the US market after it was found to be degraded. Confirming the development, a company spokesperson said the recall was carried out voluntarily and was limited to a single lot of Sotret 40 mg tablets.

According to the (USFDA), the recall comes under the Class III category, which implies that the use of or exposure to the product that is being recalled is unlikely to have any adverse health impact.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard